



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DESAUVAGE ET AL. Examiner: UNKNOWN  
Serial No.: 10/663,158 Group Art Unit: UNKNOWN  
Filed: SEPTEMBER 15, 2003 Docket: 11669.123USC1  
Due Date: DECEMBER 15, 2003  
Title: TYPE I CYTOKINE RECEPTOR TCCR

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 13, 2003.

By: 

Name: KATE GANNON

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**23552**

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.  
P.O. Box 2903, Minneapolis, MN 55402-0903  
612.332.5300

By: 

Name: Denise M. Kettelberger, Ph.D.

Reg. No.: 33,924

DKettelberger:MED:PLSklg



S/N 10/663,158

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DESAUVAGE ET AL. Examiner: UNKNOWN  
Serial No.: 10/663,158 Group Art Unit: UNKNOWN  
Filed: SEPTEMBER 15, 2003 Docket No.: 11669.123USC1  
Title: TYPE I CYTOKINE RECEPTOR TCCR

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 13, 2003.

By: 

Name: KATE CANNON

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(d), a copy of each document or other information listed on the enclosed Form 1449 is not provided because it was previously cited by or submitted to the U.S. Patent and Trademark Office in parent application, U.S. Serial No. 09/692,504 filed on October 18, 2000.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,


MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: 12 November 2003

  
Denise M. Kettelberger, Ph.D.  
Reg. No. 33,924  
DMK:MED:PLSklg



<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 11669.123USC1	Application Number: 10/663,158
	Applicant: DESAUVAGE ET AL.	
	Filing Date: 09/15/2003	Group Art Unit: UNKNOWN




## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,275,149	06/23/1981	Litman et al.			
	4,816,567	03/28/1989	Cabilly et al.			
	5,223,409	06/29/1993	Ladner et al.			
	5,403,484	04/04/1995	Ladner et al.			
	5,545,806	08/13/1996	Lonberg et al.			
	5,545,807	08/13/1996	Surani et al.			
	5,569,825	10/29/1996	Lonberg et al.			
	5,571,698	11/05/1996	Ladner et al.			
	5,625,126	04/29/1997	Lonberg et al.			
	5,633,425	05/27/1997	Lonberg et al.			
	5,658,570	08/19/1997	Newman et al.			
	5,681,722	10/28/1997	Newman et al.			
	5,693,780	12/02/1997	Newman et al.			
	5,750,105	05/12/1998	Newman et al.			
	5,750,373	05/12/1998	Garrard et al.			
	5,756,096	05/26/1998	Newman et al.			
	5,792,850	08/1998	Baumgartner et al.			
	5,925,735	07/1999	Baumgartner et al.			
	6,080,406	06/2000	Baumgartner et al.			

## FOREIGN PATENT DOCUMENTS


	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 97/44455	11/27/1997	PCT				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 11669.123USC1	Application Number: 10/663,158
	Applicant: DESAUVAGE ET AL.	
	Filing Date: 09/15/2003	Group Art Unit: UNKNOWN


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucleic Acids Research</i> , Vol. 25, pp. 3389-3402 (1997)
		Bazan, J., "Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87, pp. 6934-6938 (1990)
		Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes," <i>The Journal of Immunology</i> , Vol. 147, No. 1, pp. 86-95 (1991)
		Bolton, C., "Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications of multiple sclerosis treatment," <i>Multiple Sclerosis</i> , Vol. 1, p. 143 (1995)
		Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors," <i>Nucl. Acids Res.</i> , Vol. 13, No. 12, pp. 4431-4443 (1985)
		Chambers and Allison, "Co-stimulation in T cell responses," <i>Current Opinion in Immunology</i> , Vol. 9, No. 3, pp. 396-404 (June 1997)
		Clackson et al., "Making antibody fragments using phage display libraries," <i>Nature</i> , Vol. 352, pp. 624-628 (1991)
		Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> , New York, Alan R. Liss, Inc., pp. 77-96 (1985)
		Constant, S. L. et al., "Induction of Th1 and Th2 CD4+ T Cell Responses: The alternative approaches," <i>Annual Review of Immunology</i> , Vol. 15, pp. 297-322 (1997)
		Cosman, D., "The Hematopoietin Receptor Superfamily," <i>Cytokine</i> , Vol. 5, No. 2, pp. 95-106 (March 1993)
		Finn and Lotze, "Introduction: Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer," <i>Journal of Immunotherapy</i> , Vol. 21, No. 2, pp. 114-118 (March 1998)
		Fishwild et al., "High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice," <i>Nature Biotechnology</i> , Vol. 14, No. 7, pp. 845-851 (July 1996)
		Heid et al., "Real time quantitative PCR," <i>Genome Research</i> , Vol. 6, No. 10, pp. 986-994 (1996)
		Hoogenboom and Winter, "By-passing immunization: human antibodies from synthetic repertoires of germline V <sub>H</sub> gene segments rearranged in vitro," <i>J. Mol. Biol.</i> , Vol. 227, pp. 381-388 (1992)
		Hsieh, C.S. et al., "Development of T <sub>H</sub> 1 CD4 <sup>+</sup> T Cells Through IL-12 Produced by Listeria-Induced Macrophages," <i>Science</i> , Vol. 260, pp. 547-549 (1993)
		Huhtaniemi et al., "Transgenic and knockout mouse models for the study of luteinizing hormone and luteinizing hormone receptor function," <i>Molecular and Cellular Endocrinology</i> , Vol. 187, Nos. 1-2, pp. 49-56 (2002)
		Jenkins, M., "The ups and downs of T cell costimulation," <i>Immunity</i> , Vol. 1, No. 6, pp. 443-446 (September 1994)
		Jones, et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse," <i>Nature</i> , Vol. 321, pp. 522-525 (May 29, 1986)
		June et al., "The B7 and CD28 receptor families," <i>Immunology Today</i> , Vol. 15, No. 7, pp. 321-331 (July 1994)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449*  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.123USC1	Application Number: 10/663,158
	Applicant: DESAUVAGE ET AL.	
	Filing Date: 09/15/2003	Group Art Unit: UNKNOWN

	Kaplan, M. H. et al., "Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice," <i>Nature</i> , Vol. 382, pp. 174-177 (1996)
	Kohler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> , Vol. 256, pp. 495-497 (August 7, 1975)
	Kuhn, R. et al., "Generation and analysis of Interleukin-4 deficient mice," <i>Science</i> , Vol. 254, pp. 707-710 (1991)
	Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, No. 15, pp. 8099-8103 (July 22, 1997)
	Le Gros, G. et al., "Generation of Interleukin 4 (IL-4)-producing Cells in Vivo and In Vitro: IL-2 and IL-4 Are Required For In Vivo Generation of IL-4-producing Cells," <i>Journal of Experimental Medicine</i> , Vol. 172, pp. 921-929 (1990)
	Linsey and Ledbetter, "The Role of the CD28 receptor during T cell responses to antigen," <i>Annu. Rev. Immunol.</i> , Vol. 11, pp. 191-212 (1993)
	Lonberg and Huszar, "Human antibodies from transgenic mice," <i>International Reviews of Immunology</i> , Vol. 13, No. 1, pp. 65-93 (1995)
	Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," <i>Nature</i> , Vol. 368, No. 6474, pp. 856-859 (April 28, 1994)
	Lynch et al., "Flt3 ligand induces tumor regression and antitumor immune responses in vivo," <i>Nature Medicine</i> , Vol. 3, No. 6, pp. 625-631 (June 1997)
	Magram, J. et al., "IL-12-deficient mice are defective in IFN $\gamma$ production and type 1 cytokine responses," <i>Immunity</i> , Vol. 4, pp. 471-481 (1996)
	Mak et al., <i>Nat. Rev. Immunol.</i> , Vol. 1, pp. 11-19 (2001)
	Marks et al., "By-passing immunization: building high affinity human antibodies by chain shuffling," <i>Bio/Technology</i> , Vol. 10, pp. 779-783 (1992)
	Marks, et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage," <i>J. Mol. Biol.</i> , Vol. 222, pp. 581-597 (1991)
	Melero et al., "Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors," <i>Nature Medicine</i> , Vol. 3, No. 6, pp. 682-685 (June 1997)
	Morrison, S., "Immunology: Success in specification," <i>Nature</i> , Vol. 386, No. 6474, pp. 812-813 (April 28, 1994)
	NCBI Listing of nucleotide and protein sequences for TCCR, dated November 25, 2002
	Neuberger, M., "Generating high-avidity human Mabs in mice," <i>Nature Biotechnology</i> , Vol. 14, No. 7, p. 826 (July 1996)
	Noben-Trauth, N. et al., "An Interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 10838-10843 (1997)
	O-Garra, A., "Cytokines induce the development of functionally heterogeneous T helper cell subsets," <i>Immunity</i> , Vol. 8, pp. 275-283 (1998)
	O'Shea et al., <i>Nat. Rev. Immunol.</i> , Vol. 2, pp. 37-45 (2002)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 11669.123USC1	Application Number: 10/663,158
	Applicant: DESAUVAGE ET AL.	
	Filing Date: 09/15/2003	Group Art Unit: UNKNOWN

	Presta, L., "Antibody Engineering," <i>Curr. Op. Struct. Biol.</i> , Vol. 2, pp. 593-596 (1992)
	Proudfoot et al., <i>Immunol. Rev.</i> , Vol. 177, pp. 246-256 (2000)
	Riechmann et al., "Reshaping Human Antibodies for Therapy," <i>Nature</i> , Vol. 332, pp. 323-327 (March 24, 1988)
	Romagnani, S. et al., "Human Th1 and Th2 cells: functional properties, mechanisms of development and role in diseases," <i>Allergologie</i> , Muenchen-DeisenhDE:Dustri Verlag, Vol. 18, No. 4, pp. 175-179 (1996)
	Schwartz, R., "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," <i>Cell</i> , Vol. 71, No. 7, pp. 1065-1068 (December 24, 1992)
	Seder, R. A. et al., "Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon $\gamma$ production and diminishes interleukin 4 inhibition of such priming," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 10188-10192 (1993)
	Shimoda, K. et al., "Lack of IL-4 induced Th2 response and IgE class switching in mice with disrupted Stat6 gene," <i>Nature</i> , Vol. 380, pp. 630-633 (1996)
	Sprecher et al., "Cloning and Characterization of a Novel Class I Cytokine Receptor," <i>Biochem. &amp; Biophys. Res. Comm.</i> , Vol. 246, pp. 82-90 (1998)
	Stewart et al., "Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor," <i>Nature</i> , Vol. 359, No. 6390, pp. 76-79 (September 3, 1992)
	Swain et al., "Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development," <i>Immunol. Rev.</i> , Vol. 123, pp. 115-144 (1991)
	Thimmappaya et al., "Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection," <i>Cell</i> , Vol. 31 (3 Pt 2), pp. 543-551 (December 1982)
	Umetsu and DeKruyff, "Th1 and Th2 CD4+ Cells in the Pathogenesis of Allergic Diseases," <i>Soc. Exp. Biol. Med.</i> , Vol. 215, pp. 11-20 (1997)
	Urdal, D. L., "Cytokine Receptors," <i>Ann. Reports Med. Chem.</i> , Chapter 23, Vol. 26, pp. 221-228 (1991)
	Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites," <i>Gene</i> , Vol. 34, No. 2-3, pp. 315-323 (1985)
	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin," <i>Philos. Trans. R. Soc. London Ser A</i> , Vol. 317, pp. 415-423 (1986)
	Wu, C. et al., "Characterization of IL-12 receptor $\beta$ 1 chain (IL-12R $\beta$ 1)-deficient mice," <i>J. Immunol.</i> , Vol. 159, pp. 1658-1665 (1997)
	Zoller and Smith, "Oligonucleotide -directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA," <i>Nucl. Acids Res.</i> , Vol. 10, No. 20, pp. 6487-6500 (1982)

**23552**

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	